Newsbenzinga
Merck Says Investigational Skin Therapy Shows Potential
· Published
Article summary
Merck presented positive Phase 2b trial results for tulisokibart, demonstrating clear clinical efficacy to support Phase 3 development.
An excerpt from the original article.
Comments —
Loading comments…